Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

KNTE | Kinnate Biopharma Inc

Index	-	P/E	-	EPS (ttm)	-2.82	Insider Own	57.98%	Shs Outstand	44.34M	Perf Week	0.00%
Market Cap	65.93M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	51.59%	Shs Float	19.79M	Perf Month	-39.13%
Income	-127.16M	PEG	-	EPS next Q	-0.66	Inst Own	27.58%	Short Float / Ratio	4.73% / 4.64	Perf Quarter	-53.80%
Sales	0.00M	P/S	-	EPS this Y	7.90%	Inst Trans	0.95%	Short Interest	0.94M	Perf Half Y	-77.09%
Book/sh	4.20	P/B	0.33	EPS next Y	52.51%	ROA	-47.09%	Target Price	27.71	Perf Year	-88.98%
Cash/sh	3.92	P/C	0.36	EPS next 5Y	-	ROE	-53.95%	52W Range	1.32 - 12.65	Perf YTD	-77.05%
Dividend	-	P/FCF	-	EPS past 5Y	-96.74%	ROI	-63.46%	52W High	-88.93%	Beta	0.26
Dividend %	-	Quick Ratio	11.96	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.14%	ATR	0.17
Employees	84	Current Ratio	11.96	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	28.82	Volatility	9.98% 9.79%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-11.20%	Profit Margin	-	Rel Volume	0.25	Prev Close	1.38
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 08 AMC	Payout	-	Avg Volume	201.56K	Price	1.40
Recom	1.25	SMA20	-20.25%	SMA50	-37.72%	SMA200	-67.10%	Volume	50,916	Change	1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-22	Downgrade	Stifel	Buy → Hold	$35 → $11
Jul-28-22	Initiated	H.C. Wainwright	Buy	$33
Sep-27-21	Initiated	Jefferies	Buy	$46
Sep-23-21	Initiated	Stifel	Buy	$32
Jul-13-21	Initiated	William Blair	Outperform
May-04-21	Resumed	Piper Sandler	Overweight	$52
Dec-28-20	Initiated	Wedbush	Outperform	$48
Dec-28-20	Initiated	SVB Leerink	Outperform	$52
Dec-28-20	Initiated	Piper Sandler	Overweight	$60
Dec-28-20	Initiated	Goldman	Buy	$48

Sep-19-23 10:00AM	Dell upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly) -11.76%
Sep-18-23 07:15PM	Early-stage cancer drug company to cut 70% of workforce, halt programs (American City Business Journals)
04:10PM	Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring (GlobeNewswire)
Aug-08-23 04:05PM	Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire) -5.38%
Jun-01-23 04:05PM	Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
10:58AM	Loading…
May-31-23 10:58AM	These 2 Strong Buy Penny Stocks Could Surge 200% (or More), Says Wedbush (TipRanks) +13.76%
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey)
May-11-23 04:05PM	Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-10-23 08:46AM	Why Earnings Season Could Be Great for Kinnate Biopharma (KNTE) (Zacks)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 02:35PM	Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance (GlobeNewswire)
02:30PM	First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma (GlobeNewswire)
Mar-15-23 04:05PM	Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
Mar-14-23 06:09PM	Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting (GlobeNewswire)
Feb-21-23 04:05PM	Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China (GlobeNewswire) -11.55%
04:05PM	Loading…
Feb-14-23 04:05PM	Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor (GlobeNewswire)
Feb-06-23 04:05PM	Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 04:05PM	Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director (GlobeNewswire)
Jan-17-23 04:05PM	Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium (GlobeNewswire)
Jan-12-23 08:21AM	We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate (Simply Wall St.)
Nov-10-22 04:05PM	Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
09:55AM	Can Kinnate Biopharma Inc. (KNTE) Climb 305% to Reach the Level Wall Street Analysts Expect? (Zacks)
Oct-11-22 04:05PM	Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial (GlobeNewswire)
12:00PM	Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-10-22 02:24PM	A Kinnate Biopharma Inc. (NASDAQ:KNTE) insider increased their holdings by 1,715% last year (Simply Wall St.)
Sep-21-22 04:05PM	Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor (GlobeNewswire)
Sep-15-22 04:05PM	Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit (GlobeNewswire)
09:39AM	Harvard Universitys Latest Portfolio: 10 Best Biotech Stock Picks (Insider Monkey)
Aug-30-22 04:05PM	Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-11-22 04:05PM	Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates (GlobeNewswire) -10.05%
06:15AM	Loading…
Aug-07-22 06:15AM	Over 100% Upside: Analysts See an Appealing Entry Point in These 3 Strong Buy Stocks (TipRanks)
Aug-05-22 06:57AM	We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely (Simply Wall St.)
Aug-04-22 02:22PM	Kinnate Biopharma, led by a former vaccine CEO, hopes to reshape cancer drugs (American City Business Journals) +13.22%
Aug-02-22 04:05PM	Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Jun-01-22 04:05PM	Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-26-22 05:00PM	Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022 (GlobeNewswire) -9.50%
May-12-22 04:05PM	Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates (GlobeNewswire) +7.88%
May-03-22 02:02PM	A Kinnate Biopharma Inc. (NASDAQ:KNTE) insider increased their holdings by 1,715% last year (Simply Wall St.)
Apr-18-22 08:00AM	Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248 (GlobeNewswire) -5.02%
Apr-08-22 04:30PM	Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-28-22 04:05PM	Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates (GlobeNewswire)
Mar-08-22 06:00PM	Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +8.25%
Mar-07-22 06:00AM	Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress (GlobeNewswire)
Feb-28-22 04:05PM	Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire) -5.35%
Feb-26-22 07:19AM	Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-14-22 08:00AM	Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting (GlobeNewswire) -5.58%
Feb-09-22 08:16AM	Gabelli Convertible and Income Securities Fund Declares First Quarter Distribution of $0.12 Per Share (Business Wire) +5.67%
Feb-07-22 04:05PM	Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-19-22 04:05PM	Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) -15.74%
Jan-18-22 04:05PM	Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248 (GlobeNewswire)
Jan-06-22 04:05PM	Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones (GlobeNewswire) -5.12%
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com)
Dec-20-21 04:05PM	Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings (GlobeNewswire)
Dec-16-21 04:05PM	Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index (GlobeNewswire) -5.88%
Nov-10-21 04:05PM	Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-08-21 04:05PM	Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-21 08:00AM	Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study (GlobeNewswire)
Oct-28-21 04:05PM	Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer (GlobeNewswire)
Oct-07-21 09:00AM	Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference (GlobeNewswire)
Sep-30-21 04:30PM	Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference (GlobeNewswire)
Sep-13-21 08:00AM	Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference (GlobeNewswire) -5.94%
Aug-30-21 07:39AM	Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation (Simply Wall St.)
Aug-16-21 04:05PM	Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results (GlobeNewswire) -11.95%
Aug-12-21 08:30AM	Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings? (Zacks)
Jul-28-21 11:24AM	Is Kinnate Biopharma Inc. (KNTE) A Good Stock To Buy? (Insider Monkey)
Jul-27-21 08:00AM	Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-07-21 04:05PM	Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-28-21 08:00AM	Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors (GlobeNewswire)
Jun-07-21 08:00AM	Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires (GlobeNewswire)
Jun-04-21 08:00AM	Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021 (GlobeNewswire)
May-25-21 04:05PM	Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
May-17-21 04:05PM	Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787 (GlobeNewswire)
May-13-21 04:02PM	Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture (GlobeNewswire) -5.65%
May-10-21 08:00AM	Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting (Business Wire)
Apr-30-21 08:00AM	Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors (GlobeNewswire)
Mar-29-21 04:05PM	Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results (GlobeNewswire) -7.03%
Mar-19-21 04:05PM	Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index (GlobeNewswire)
Mar-03-21 12:50AM	We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely (Simply Wall St.)
Feb-11-21 04:05PM	Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-31-20 03:42PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy (TipRanks)
Dec-28-20 10:04AM	Benzinga's Top Upgrades, Downgrades For December 28, 2020 (Benzinga) +7.55%
Dec-07-20 04:05PM	Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Dec-04-20 04:30PM	Biotech IPOs Of Seer, Silverback Jump As Trading Gets Underway (Investor's Business Daily) +11.35%
Dec-03-20 05:18PM	Kinnate Biopharma Stock Nearly Doubles in Debut. More Deals Are Coming. (Barrons.com)
04:33PM	Kinnate Biopharma Stock Doubles As IPO Begins Trading (Investor's Business Daily)
12:29PM	Kinnate Biopharma stock more than doubles in trading debut (MarketWatch)
06:13AM	Kinnate Biopharma upsizes IPO and prices above range at $20 a share (MarketWatch)
Dec-02-20 10:02PM	Kinnate Biopharma Announces Pricing of Initial Public Offering (GlobeNewswire)

Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tananbaum James B.	Director	May 08	Buy	2.80	1,780,000	4,984,000	3,525,957	May 10 05:49 PM
Foresite Capital Management IV	10% Owner	May 08	Buy	2.80	1,780,000	4,984,000	3,525,957	May 10 05:42 PM
GORDON CARL L	Director	May 05	Buy	2.82	981,023	2,766,485	1,368,339	May 08 05:11 PM
ORBIMED ADVISORS LLC	Director	May 05	Buy	2.82	981,023	2,766,485	1,368,339	May 08 05:22 PM
ORBIMED ADVISORS LLC	Director	May 04	Buy	2.75	479,909	1,319,750	4,738,453	May 08 05:22 PM
GORDON CARL L	Director	May 04	Buy	2.75	479,909	1,319,750	4,738,453	May 08 05:11 PM
ORBIMED ADVISORS LLC	Director	May 02	Buy	2.67	338,262	903,160	4,425,462	May 02 09:34 PM
GORDON CARL L	Director	May 02	Buy	2.67	338,262	903,160	4,425,462	May 02 09:38 PM
GORDON CARL L	Director	May 01	Buy	2.62	716,157	1,876,331	4,204,852	May 02 09:38 PM
ORBIMED ADVISORS LLC	Director	May 01	Buy	2.62	716,157	1,876,331	4,204,852	May 02 09:34 PM
ORBIMED ADVISORS LLC	Director	Apr 28	Buy	2.55	350,749	894,410	3,737,784	May 02 09:34 PM
GORDON CARL L	Director	Apr 28	Buy	2.55	350,749	894,410	3,737,784	May 02 09:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KNTE | Kinnate Biopharma Inc

Upgrade your FINVIZ experience